MSN to launch generic anti-COVID pill Molnupiravir

New Delhi: Pharmaceuticals firm MSN Group on Thursday said it will launch its generic anti-COVID-19 pill Molnupiravir under the brand 'Molulow' in India.

The group is all set to launch the generic Molnupiravir 200 mg capsules and it is being manufactured at its USFDA and MHRA accredited facility based out of Hyderabad, MSN Group said in a statement. Molulow will come as a pack of 4x10 capsule strips with each capsule in 200 mg strength.

Also Read:Dr Reddys to launch anti-COVID drug Molnupiravir under brand name Molflu at Rs 35 per capsule

Last month, the Drugs Controller General of India (DCGI) approved Molnupiravir for restricted use in emergency situation (EUA) in India. Other homegrown pharma majors such as Strides Pharma, Dr Reddy's, Sun Pharma, Cipla, Hetero, Torrent, Optimus and Brinton Pharma have already announced plans to roll out their generic versions of the drug.

Also Read:Molnupiravir has major safety concerns, hence not part of National Protocol: ICMR chief Balram Bhargava